$630 Billion is the total value of Rhenman & Partners Asset Management AB's 107 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 109.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SHPG | New | Shire Plcsponsored adr | $26,595,290,000 | – | 409,858 | +100.0% | 4.22% | – |
| LLY | Buy | Eli Lilly & Co | $20,466,300,000 | +110492.8% | 255,000 | +8.5% | 3.25% | -1.1% |
| New | Pfizer Inc | $18,809,874,000 | – | 555,355 | +100.0% | 2.99% | – | |
| AGN | Buy | Allergan Plc | $18,309,645,000 | +152264.5% | 79,500 | +52.9% | 2.91% | +36.3% |
| UNH | Buy | Unitedhealth Group Inc | $18,200,000,000 | +151541.4% | 130,000 | +52.9% | 2.89% | +35.7% |
| INCY | Buy | Incyte Corp | $17,443,650,000 | +128190.4% | 185,000 | +8.8% | 2.77% | +14.8% |
| New | Gilead Sciences Inc | $16,401,892,000 | – | 207,304 | +100.0% | 2.60% | – | |
| New | Medtronic Plc | $14,608,339,000 | – | 169,078 | +100.0% | 2.32% | – | |
| CVS | Buy | Cvs Health Corp | $14,238,400,000 | +123830.7% | 160,000 | +33.3% | 2.26% | +10.8% |
| BMY | Buy | Bristol-Myers Squibb Co | $12,779,040,000 | +126726.5% | 237,000 | +73.0% | 2.03% | +13.5% |
| MRK | New | Merck & Co. Inc. | $12,482,000,000 | – | 200,000 | +100.0% | 1.98% | – |
| TEVA | New | Teva Pharmaceutical-Sp Adr | $12,422,700,000 | – | 270,000 | +100.0% | 1.97% | – |
| ZBH | Buy | Zimmer Biomet Holdings Inc | $11,051,700,000 | +129205.0% | 85,000 | +19.7% | 1.76% | +15.6% |
| ARIA | Buy | Ariad Pharmaceuticals Inc | $9,240,750,000 | +199959.5% | 675,000 | +8.0% | 1.47% | +79.0% |
| New | Anthem Inc | $8,450,155,000 | – | 67,434 | +100.0% | 1.34% | – | |
| HCA | Buy | Hca Holdings Inc | $8,319,300,000 | +107928.8% | 110,000 | +10.0% | 1.32% | -3.4% |
| ALKS | Buy | Alkermes Plc | $8,258,421,000 | +140804.6% | 175,599 | +29.5% | 1.31% | +26.0% |
| VRTX | Buy | Vertex Pharmaceuticals Inc | $6,977,934,000 | +135105.1% | 80,013 | +33.4% | 1.11% | +21.0% |
| ABBV | Buy | Abbvie Inc | $6,937,700,000 | +159976.1% | 110,000 | +57.1% | 1.10% | +43.1% |
| DXCM | Buy | Dexcom Inc | $5,697,900,000 | +130495.9% | 65,000 | +18.2% | 0.90% | +16.8% |
| RIGL | Buy | Rigel Pharmaceuticals Inc | $5,138,000,000 | +270891.6% | 1,400,000 | +64.7% | 0.82% | +142.1% |
| KITE | Buy | Kite Pharma Inc | $5,027,400,000 | +143540.0% | 90,000 | +28.6% | 0.80% | +28.3% |
| TMO | New | Thermo Fisher Scientific Inc | $3,976,500,000 | – | 25,000 | +100.0% | 0.63% | – |
| ARRY | Buy | Array Biopharma Inc | $3,712,500,000 | +281790.7% | 550,000 | +48.6% | 0.59% | +152.1% |
| UHS | New | Universal Health Services-B | $3,696,600,000 | – | 30,000 | +100.0% | 0.59% | – |
| DVA | New | Davita Inc | $3,633,850,000 | – | 55,000 | +100.0% | 0.58% | – |
| PRGO | Buy | Perrigo Co Plc | $3,231,550,000 | +178143.2% | 35,000 | +75.0% | 0.51% | +59.3% |
| DVAX | Buy | Dynavax Technologies Corp | $3,147,000,000 | +143795.7% | 300,000 | +100.0% | 0.50% | +28.9% |
| PTLA | Buy | Portola Pharmaceuticals Inc | $2,743,482,000 | +110613.6% | 120,805 | +15.1% | 0.44% | -0.9% |
| KERX | Buy | Keryx Biopharmaceuticals | $2,655,589,000 | +89013.7% | 500,111 | +11.1% | 0.42% | -20.2% |
| RAD | New | Rite Aid Corp | $2,307,000,000 | – | 300,000 | +100.0% | 0.37% | – |
| TSRO | New | Tesaro Inc | $2,155,160,000 | – | 21,500 | +100.0% | 0.34% | – |
| ITCI | Buy | Intra-Cellular Therapies Inc | $2,057,400,000 | +45988.7% | 135,000 | +17.4% | 0.33% | -58.8% |
| TNDM | Buy | Tandem Diabetes Care Inc | $1,792,440,000 | +113633.5% | 234,000 | +12.0% | 0.28% | +1.8% |
| JNJ | New | Johnson & Johnson | $1,771,950,000 | – | 15,000 | +100.0% | 0.28% | – |
| ICPT | New | Intercept Pharmaceuticals In | $1,645,900,000 | – | 10,000 | +100.0% | 0.26% | – |
| OREXQ | New | Orexigen Therapeutics Inc | $398,400,000 | – | 120,000 | +100.0% | 0.06% | – |
| WFC | New | Wells Fargo & Co | $200,234,000 | – | 4,522 | +100.0% | 0.03% | – |
| CAT | New | Caterpillar Inc | $193,341,000 | – | 2,178 | +100.0% | 0.03% | – |
| QCOM | New | Qualcomm Inc | $196,526,000 | – | 2,869 | +100.0% | 0.03% | – |
| HAL | New | Halliburton Co | $189,887,000 | – | 4,231 | +100.0% | 0.03% | – |
| XOM | New | Exxon Mobil Corp | $183,463,000 | – | 2,102 | +100.0% | 0.03% | – |
| IBM | New | Intl Business Machines Corp | $181,566,000 | – | 1,143 | +100.0% | 0.03% | – |
| MSFT | New | Microsoft Corp | $180,864,000 | – | 3,140 | +100.0% | 0.03% | – |
| F | New | Ford Motor Co | $176,355,000 | – | 14,611 | +100.0% | 0.03% | – |
| JPM | New | Jpmorgan Chase & Co | $178,994,000 | – | 2,688 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.